Deciphering the Role of Host Genetics in Susceptibility to Severe COVID-19

Coronavirus disease-19 (COVID-19) describes a set of symptoms that develop following infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Whilst COVID-19 disease is most serious in patients with significant co-morbidities, the reason for healthy individuals succumbing to fulminant infection is largely unexplained. In this review, we discuss the most recent findings in terms of clinical features and the host immune response, and suggest candidate immune pathways that may be compromised in otherwise healthy individuals with fulminating COVID-19. On the basis of this early knowledge we reason a potential genetic effect on host immune response pathways leading to increased susceptibility to SARS-CoV-2 infection. Understanding these pathways may help not only in unraveling disease pathogenesis, but also in suggesting targets for therapy and prophylaxis. Importantly such insight should instruct efforts to identify those at increased risk in order to institute preventative measures, such as prophylactic medication and/or vaccination, when such opportunities arise in the later phases of the current pandemic or during future similar pandemics.

[1]  Yanchen Zhou,et al.  Protease inhibitors targeting coronavirus and filovirus entry , 2015, Antiviral Research.

[2]  J. Welch,et al.  The Evolution and Genetics of Virus Host Shifts , 2014, PLoS pathogens.

[3]  B. Amulic,et al.  Neutrophil extracellular traps , 2011, Current Biology.

[4]  Hong Zhou,et al.  Extraordinary GU-rich single-strand RNA identified from SARS coronavirus contributes an excessive innate immune response , 2012, Microbes and Infection.

[5]  Jason R. Madsen,et al.  Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model , 2010, Antiviral Research.

[6]  Makoto Takeda,et al.  Efficient Activation of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein by the Transmembrane Protease TMPRSS2 , 2010, Journal of Virology.

[7]  E. Price-Haywood,et al.  Hospitalization and Mortality among Black Patients and White Patients with Covid-19 , 2020, The New England journal of medicine.

[8]  Xuhui Huang,et al.  Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro , 2020, Antiviral Research.

[9]  J. Meller,et al.  Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. , 2011, Blood.

[10]  Taojiao Wang,et al.  Clinical and immunologic features in severe and moderate forms of Coronavirus Disease 2019 , 2020, medRxiv.

[11]  P. Österlund,et al.  Severe Acute Respiratory Syndrome Coronavirus Fails To Activate Cytokine-Mediated Innate Immune Responses in Cultured Human Monocyte-Derived Dendritic Cells , 2005, Journal of Virology.

[12]  N. McGovern,et al.  STAT2 deficiency and susceptibility to viral illness in humans , 2013, Proceedings of the National Academy of Sciences.

[13]  Burkhard Ludewig,et al.  Ribose 2′-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5 , 2011, Nature Immunology.

[14]  Lei Liu,et al.  Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 , 2020, medRxiv.

[15]  E. Holmes,et al.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding , 2020, The Lancet.

[16]  Wu Zhong,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[17]  Jacques Fellay,et al.  A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection , 2020, Cell.

[18]  Stefano Volpi,et al.  On the Alert for Cytokine Storm: Immunopathology in COVID‐19 , 2020, Arthritis & rheumatology.

[19]  A. Svejgaard,et al.  Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin , 1997, The Lancet.

[20]  R. Caporali,et al.  COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country , 2020, Pediatric Rheumatology.

[21]  S. Weiss,et al.  MDA5 Is Critical to Host Defense during Infection with Murine Coronavirus , 2015, Journal of Virology.

[22]  A. Smahi,et al.  TLR3 Deficiency in Patients with Herpes Simplex Encephalitis , 2007, Science.

[23]  J. Peiris,et al.  Mannose-Binding Lectin in Severe Acute Respiratory Syndrome Coronavirus Infection , 2005, The Journal of infectious diseases.

[24]  Lianfeng Zhang,et al.  Mice transgenic for human angiotensin-converting enzyme 2 provide a model for SARS coronavirus infection. , 2007, Comparative medicine.

[25]  Y. Lau,et al.  Chemokine up-regulation in SARS-coronavirus–infected, monocyte-derived human dendritic cells , 2005, Blood.

[26]  H. Garner,et al.  Dynamic Innate Immune Responses of Human Bronchial Epithelial Cells to Severe Acute Respiratory Syndrome-Associated Coronavirus Infection , 2010, PloS one.

[27]  M. Metra,et al.  Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy , 2020, Autoimmunity Reviews.

[28]  M. Zuckerman,et al.  Terminal complement inhibition dampens the inflammation during COVID‐19 , 2020, British journal of haematology.

[29]  Lisa E. Gralinski,et al.  Attenuation and Restoration of Severe Acute Respiratory Syndrome Coronavirus Mutant Lacking 2′-O-Methyltransferase Activity , 2014, Journal of Virology.

[30]  Amit N. Patel,et al.  RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis , 2020, The Lancet.

[31]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[32]  Ton de Jong,et al.  Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques , 2004, Nature Medicine.

[33]  Jincun Zhao,et al.  A Transmembrane Serine Protease Is Linked to the Severe Acute Respiratory Syndrome Coronavirus Receptor and Activates Virus Entry , 2010, Journal of Virology.

[34]  J. Casanova,et al.  Human inborn errors of immunity to herpes viruses. , 2020, Current opinion in immunology.

[35]  E. Glaser The randomized clinical trial. , 1972, The New England journal of medicine.

[36]  Kurt M Kunz A Trial of Lopinavir-Ritonavir in Covid-19. , 2020, The New England journal of medicine.

[37]  T. Jacques,et al.  Human IFNAR2 deficiency: Lessons for antiviral immunity , 2015, Science Translational Medicine.

[38]  Wu Zhong,et al.  Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro , 2020, Cell Discovery.

[39]  Jaume Torres,et al.  Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome , 2015, Virology.

[40]  J. Loo,et al.  Association of HLA class I with severe acute respiratory syndrome coronavirus infection , 2003, BMC Medical Genetics.

[41]  Susanna K. P. Lau,et al.  Coronavirus Genomics and Bioinformatics Analysis , 2010, Viruses.

[42]  Duanqing Pei,et al.  Treating COVID-19 with Chloroquine , 2020, Journal of molecular cell biology.

[43]  F. Aoki,et al.  Severe Acute Respiratory Syndrome-Related Coronavirus Is Inhibited by Interferon-α , 2004, The Journal of infectious diseases.

[44]  S. Elledge,et al.  Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency , 2018, The Journal of experimental medicine.

[45]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[46]  Kwok-Hung Chan,et al.  Discovery of Seven Novel Mammalian and Avian Coronaviruses in the Genus Deltacoronavirus Supports Bat Coronaviruses as the Gene Source of Alphacoronavirus and Betacoronavirus and Avian Coronaviruses as the Gene Source of Gammacoronavirus and Deltacoronavirus , 2012, Journal of Virology.

[47]  Ö. Strannegård,et al.  In vitro inhibition of SARS virus replication by human interferons , 2004, Scandinavian journal of infectious diseases.

[48]  L. Lagae,et al.  Inborn errors in RNA polymerase III underlie severe varicella zoster virus infections. , 2017, The Journal of clinical investigation.

[49]  O. Tsang,et al.  Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study , 2020, The Lancet Infectious Diseases.

[50]  J. Casanova,et al.  Varicella-zoster virus CNS vasculitis and RNA polymerase III gene mutation in identical twins , 2018, Neurology: Neuroimmunology & Neuroinflammation.

[51]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[52]  Jiyuan Zhang,et al.  Pathological findings of COVID-19 associated with acute respiratory distress syndrome , 2020, The Lancet Respiratory Medicine.

[53]  Barney S. Graham,et al.  Publisher Correction: Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis , 2018, Scientific Reports.

[54]  P. Hart,et al.  A phase 1/2 trial to evaluate the pharmacokinetics, safety, and efficacy of NI-03 in patients with chronic pancreatitis: study protocol for a randomized controlled trial on the assessment of camostat treatment in chronic pancreatitis (TACTIC) , 2019, Trials.

[55]  J. Habbema,et al.  Association of SARS susceptibility with single nucleic acid polymorphisms of OAS1 and MxA genes: a case-control study , 2006, BMC infectious diseases.

[56]  B. Lambrecht,et al.  Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial , 2020, Trials.

[57]  Alimuddin Zumla,et al.  Coronaviruses — drug discovery and therapeutic options , 2016, Nature Reviews Drug Discovery.

[58]  W. Zuo,et al.  Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov , 2020, bioRxiv.

[59]  P. Theocharis,et al.  Hyperinflammatory shock in children during COVID-19 pandemic , 2020, The Lancet.

[60]  M. Netea,et al.  Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis , 2020, Cell Host & Microbe.

[61]  Brandon Michael Henry,et al.  COVID-19, ECMO, and lymphopenia: a word of caution , 2020, The Lancet Respiratory Medicine.

[62]  Jing Liu,et al.  Updated Approaches against SARS-CoV-2 , 2020, Antimicrobial Agents and Chemotherapy.

[63]  J. Sung,et al.  Association of Human-Leukocyte-Antigen Class I (B*0703) and Class II (DRB1*0301) Genotypes with Susceptibility and Resistance to the Development of Severe Acute Respiratory Syndrome , 2004, The Journal of infectious diseases.

[64]  M. Melbye,et al.  Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood. , 2001, JAMA.

[65]  M. Bosmann Complement Activation during Critical Illness: Current Findings and an Outlook in the Era of COVID-19 , 2020, American journal of respiratory and critical care medicine.

[66]  P. Hsueh,et al.  Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS‐associated coronavirus , 2004, Clinical Microbiology and Infection.

[67]  Ralph S. Baric,et al.  MyD88 Is Required for Protection from Lethal Infection with a Mouse-Adapted SARS-CoV , 2008, PLoS pathogens.

[68]  J. Casanova,et al.  Lethal Infectious Diseases as Inborn Errors of Immunity: Toward a Synthesis of the Germ and Genetic Theories. , 2020, Annual review of pathology.

[69]  Taojiao Wang,et al.  Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. , 2020, The Journal of clinical investigation.

[70]  F. Schmidt Meta-Analysis , 2008 .

[71]  M. Okano,et al.  Cohort Study , 2020, Definitions.

[72]  Neurological manifestations associated with COVID-19: a review and a call for action , 2020, Journal of Neurology.

[73]  C. Thio,et al.  IL28B and the control of hepatitis C virus infection. , 2010, Gastroenterology.

[74]  R. Baric,et al.  Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV , 2020, Nature Communications.

[75]  Linqi Zhang,et al.  Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor , 2020, Nature.

[76]  Lisa E. Gralinski,et al.  Allelic Variation in the Toll-Like Receptor Adaptor Protein Ticam2 Contributes to SARS-Coronavirus Pathogenesis in Mice , 2017, G3: Genes, Genomes, Genetics.

[77]  C. Peters,et al.  Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) , 2004, Virology.

[78]  Jingjing Xu,et al.  Rapid asymptomatic transmission of COVID-19 during the incubation period demonstrating strong infectivity in a cluster of youngsters aged 16-23 years outside Wuhan and characteristics of young patients with COVID-19: A prospective contact-tracing study , 2020, Journal of Infection.

[79]  C. Gale,et al.  Ethnic disparities in hospitalisation for COVID-19 in England: The role of socioeconomic factors, mental health, and inflammatory and pro-inflammatory factors in a community-based cohort study , 2020, Brain, Behavior, and Immunity.

[80]  G. Uzel,et al.  XMEN disease: a new primary immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus. , 2014, Blood.

[81]  S. Maskatia,et al.  COVID-19 and Kawasaki Disease: Novel Virus and Novel Case. , 2020, Hospital pediatrics.

[82]  S. Ehl,et al.  Is an infectious trigger always required for primary hemophagocytic lymphohistiocytosis? Lessons from in utero and neonatal disease , 2018, Pediatric blood & cancer.

[83]  M. Martínez Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus , 2020, Antimicrobial Agents and Chemotherapy.

[84]  John L. Sullivan,et al.  Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus , 2003, Nature.

[85]  A. Peleg,et al.  Remdesivir for the Treatment of Covid-19 - Preliminary Report. , 2020, The New England journal of medicine.

[86]  ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy , 2020, Aging.

[87]  Wei Liu,et al.  Two-Year Prospective Study of the Humoral Immune Response of Patients with Severe Acute Respiratory Syndrome , 2006, The Journal of infectious diseases.

[88]  A. Arvey,et al.  GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses , 2017, Scientific Reports.

[89]  Vineet D. Menachery,et al.  Coronavirus non-structural protein 16: Evasion, attenuation, and possible treatments , 2014, Virus Research.

[90]  J. Casanova,et al.  Lessons learned from the study of human inborn errors of innate immunity , 2019, The Journal of allergy and clinical immunology.

[91]  B. Foley,et al.  Evolutionary history, potential intermediate animal host, and cross‐species analyses of SARS‐CoV‐2 , 2020, Journal of medical virology.

[92]  Lin Cheng,et al.  Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 , 2020, Nature Medicine.

[93]  A. Singanayagam,et al.  Immunosuppression for hyperinflammation in COVID-19: a double-edged sword? , 2020, The Lancet.

[94]  R. Carlier,et al.  Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study , 2020, European Archives of Oto-Rhino-Laryngology.

[95]  J. Connors,et al.  COVID-19 and its implications for thrombosis and anticoagulation , 2020, Blood.

[96]  V. Lougaris,et al.  A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia , 2020, Journal of Allergy and Clinical Immunology.

[97]  P. Vollmar,et al.  Virological assessment of hospitalized patients with COVID-2019 , 2020, Nature.

[98]  J. M. Crawford,et al.  Targeting potential drivers of COVID-19: Neutrophil extracellular traps , 2020, The Journal of experimental medicine.

[99]  P. Ravaud,et al.  Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data , 2020, BMJ.

[100]  A. Zangrillo,et al.  Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study , 2020, The Lancet Rheumatology.

[101]  M. Gismondo,et al.  Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status , 2020, Pharmacological Research.

[102]  D. Raoult,et al.  Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial , 2020, International Journal of Antimicrobial Agents.

[103]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[104]  H. Rothan,et al.  The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak , 2020, Journal of Autoimmunity.

[105]  Takeshi Ichinohe,et al.  Severe Acute Respiratory Syndrome Coronavirus Viroporin 3a Activates the NLRP3 Inflammasome , 2019, Front. Microbiol..

[106]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[107]  C. Bode,et al.  A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial , 2020, Trials.

[108]  Ting Yu,et al.  Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study , 2020, The Lancet Respiratory Medicine.

[109]  A. Xu,et al.  Profile of specific antibodies to the SARS-associated coronavirus. , 2003, The New England journal of medicine.

[110]  M. Titécat,et al.  Distinct Immune Response in Two MERS-CoV-Infected Patients: Can We Go from Bench to Bedside? , 2014, PloS one.

[111]  M. Aepfelbacher,et al.  Dying with SARS-CoV-2 infection—an autopsy study of the first consecutive 80 cases in Hamburg, Germany , 2020, International Journal of Legal Medicine.

[112]  D. Hamer Faculty Opinions recommendation of Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[113]  T. Mogensen IRF and STAT Transcription Factors - From Basic Biology to Roles in Infection, Protective Immunity, and Primary Immunodeficiencies , 2019, Front. Immunol..

[114]  J. Casanova,et al.  Severe influenza pneumonitis in children with inherited TLR3 deficiency , 2019, The Journal of experimental medicine.

[115]  S. Perlman,et al.  Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology , 2017, Seminars in Immunopathology.

[116]  Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19) , 2020, Frontiers in Immunology.

[117]  C. Shi,et al.  SARS-Coronavirus Open Reading Frame-8b triggers intracellular stress pathways and activates NLRP3 inflammasomes , 2019, Cell Death Discovery.

[118]  J. Casanova,et al.  The 2015 IUIS Phenotypic Classification for Primary Immunodeficiencies , 2015, Journal of Clinical Immunology.

[119]  Ying Wang,et al.  COVID-19 infection: the perspectives on immune responses , 2020, Cell Death & Differentiation.

[120]  A. McMichael,et al.  T Cell Responses to Whole SARS Coronavirus in Humans1 , 2008, The Journal of Immunology.

[121]  Clinical Course and Outcomes of Critically Ill Patients With Middle East Respiratory Syndrome Coronavirus Infection , 2014 .

[122]  Lisa E. Gralinski,et al.  Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses , 2017, Science Translational Medicine.

[123]  Lin‐Fa Wang,et al.  Duration of Antibody Responses after Severe Acute Respiratory Syndrome , 2007, Emerging infectious diseases.

[124]  Min-sheng Zhu,et al.  SARS Immunity and Vaccination. , 2004, Cellular & molecular immunology.

[125]  T. Palaga,et al.  Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. , 2020, Asian Pacific journal of allergy and immunology.

[126]  M. Mahdavinia,et al.  African American children are at higher risk of COVID‐19 infection , 2020, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[127]  Allison J. Taggart,et al.  Inborn Errors of RNA Lariat Metabolism in Humans with Brainstem Viral Infection , 2018, Cell.

[128]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[129]  J. Gjedsted,et al.  Defective RNA sensing by RIG‐I in severe influenza virus infection , 2018, Clinical and experimental immunology.

[130]  G. Chatellier,et al.  Anakinra for severe forms of COVID-19: a cohort study , 2020, The Lancet Rheumatology.

[131]  Paul Kellam,et al.  The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection , 2020, The Journal of general virology.

[132]  D. Chaussabel,et al.  Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency , 2015, Science.

[133]  R. Schwartz,et al.  Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.

[134]  Steven M. Wolinsky,et al.  The role of a mutant CCR5 allele in HIV–1 transmission and disease progression , 1996, Nature Medicine.

[135]  Xiaohu Zheng,et al.  Effective treatment of severe COVID-19 patients with tocilizumab , 2020, Proceedings of the National Academy of Sciences.

[136]  L. Dodd,et al.  Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.

[137]  L. Notarangelo,et al.  NTB-A [correction of GNTB-A], a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative disease. , 2001, The Journal of experimental medicine.

[138]  R. Bruno,et al.  Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 , 2020, The New England journal of medicine.

[139]  J. Casanova,et al.  The human CIB1–EVER1–EVER2 complex governs keratinocyte-intrinsic immunity to β-papillomaviruses , 2018, The Journal of experimental medicine.

[140]  J. Knight,et al.  Neutrophil extracellular traps and thrombosis in COVID-19 , 2020, medRxiv.

[141]  Q. Bassat,et al.  Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. , 2020, JAMA network open.

[142]  T. Fung,et al.  Human Coronavirus: Host-Pathogen Interaction. , 2019, Annual review of microbiology.

[143]  Kejian Zhang,et al.  XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. , 2010, Blood.

[144]  Dennis Andersson,et al.  A retrospective cohort study , 2018 .

[145]  Jincun Zhao,et al.  Virus-Specific Memory CD8 T Cells Provide Substantial Protection from Lethal Severe Acute Respiratory Syndrome Coronavirus Infection , 2014, Journal of Virology.

[146]  Awanish Kumar,et al.  Host–Pathogen Interaction , 2017 .

[147]  Douglas R. McDonald,et al.  Selective predisposition to bacterial infections in IRAK-4–deficient children: IRAK-4–dependent TLRs are otherwise redundant in protective immunity , 2007, The Journal of experimental medicine.

[148]  Jie Hao,et al.  Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection , 2020, Frontiers of Medicine.

[149]  N. Dauby Potential impact of COVID-19 in people living with HIV: experience from previous 21st century coronaviruses epidemics , 2020, AIDS.

[150]  J. Casanova,et al.  Human genetics of infectious diseases: Unique insights into immunological redundancy. , 2017, Seminars in immunology.

[151]  Andrew J. Oler,et al.  Recurrent rhinovirus infections in a child with inherited MDA5 deficiency , 2017, The Journal of experimental medicine.

[152]  T. Kirikae,et al.  Polymorphisms of interferon-inducible genes OAS-1 and MxA associated with SARS in the Vietnamese population , 2005, Biochemical and Biophysical Research Communications.

[153]  Y. Yazdanpanah,et al.  Corticosteroids in patients hospitalized for COVID-19 pneumonia who require oxygen: observational comparative study using routine care data , 2020, Clinical Microbiology and Infection.

[154]  M. Hibberd,et al.  Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease , 1999, The Lancet.

[155]  M. Burns,et al.  Case-Control Study , 2020, Definitions.

[156]  Jun Yuan,et al.  Antibody responses to SARS-CoV-2 in patients with COVID-19 , 2020, Nature Medicine.

[157]  Y. Lau,et al.  Pathogenesis of severe acute respiratory syndrome , 2005, Current Opinion in Immunology.

[158]  F. Weber,et al.  Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response , 2016, Advances in Virus Research.

[159]  G. Hripcsak,et al.  Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 , 2020, The New England journal of medicine.

[160]  Joy Y. Feng,et al.  The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus , 2020, The Journal of Biological Chemistry.

[161]  J. Sung,et al.  ABO blood group and susceptibility to severe acute respiratory syndrome. , 2005, JAMA.

[162]  Frederic A. Fellouse,et al.  Human ACE2 receptor polymorphisms predict SARS-CoV-2 susceptibility , 2020, bioRxiv.

[163]  R. Baric,et al.  SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon , 2012, Current Opinion in Virology.

[164]  J. Casanova,et al.  Lethal Influenza in Two Related Adults with Inherited GATA2 Deficiency , 2018, Journal of Clinical Immunology.

[165]  Lei Liu,et al.  Relationship between the ABO Blood Group and the COVID-19 Susceptibility , 2020, medRxiv.

[166]  Jincun Zhao,et al.  T cell-mediated immune response to respiratory coronaviruses , 2014, Immunologic Research.

[167]  M. Katze,et al.  Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection , 2015, mBio.

[168]  Dong Yang,et al.  Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[169]  Xuetao Cao COVID-19: immunopathology and its implications for therapy , 2020, Nature Reviews Immunology.

[170]  Yi Wang,et al.  Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial , 2020, The Lancet.

[171]  Y. Ho,et al.  SARS-CoV-2: A Storm is Raging. , 2020, The Journal of clinical investigation.

[172]  J. Luban SARS-CoV-2 , 2020 .

[173]  D. Leaf,et al.  COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection , 2020, Blood.

[174]  M. T. Medina,et al.  The neurology of COVID-19 revisited: A proposal from the Environmental Neurology Specialty Group of the World Federation of Neurology to implement international neurological registries , 2020, Journal of the Neurological Sciences.

[175]  J. Casanova,et al.  Fatal Cytomegalovirus Infection in an Adult with Inherited NOS2 Deficiency. , 2020, The New England journal of medicine.

[176]  Cisca Wijmenga,et al.  The MHC locus and genetic susceptibility to autoimmune and infectious diseases , 2017, Genome Biology.

[177]  F. A. Lagunas-Rangel,et al.  High IL‐6/IFN‐γ ratio could be associated with severe disease in COVID‐19 patients , 2020, Journal of medical virology.

[178]  J. Casanova,et al.  The human genetic determinism of life-threatening infectious diseases: genetic heterogeneity and physiological homogeneity? , 2020, Human Genetics.

[179]  Chuan Qin,et al.  Dysregulation of immune response in patients with COVID-19 in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[180]  H. Feldmann,et al.  Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection , 2020, Proceedings of the National Academy of Sciences.

[181]  F. Blasi,et al.  Complement activation in patients with COVID-19: A novel therapeutic target , 2020, Journal of Allergy and Clinical Immunology.

[182]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[183]  L. Poon,et al.  Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia : a prospective study , 2003 .

[184]  A. Tam,et al.  Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta-analysis , 2020, Gastroenterology.

[185]  G. Navis,et al.  Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis , 2004, The Journal of pathology.

[186]  Ruth R. Montgomery,et al.  Mx1 reveals innate pathways to antiviral resistance and lethal influenza disease , 2016, Science.

[187]  J. Casanova,et al.  The 2017 IUIS Phenotypic Classification for Primary Immunodeficiencies , 2017, Journal of Clinical Immunology.

[188]  H. Doerr,et al.  Treatment of SARS with human interferons , 2003, The Lancet.

[189]  R. Kassab,et al.  A word of caution. , 2000, International journal of cardiology.

[190]  A. Mantovani,et al.  ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy , 2020, medRxiv.

[191]  André Machado Siqueira,et al.  Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. , 2020, JAMA network open.

[192]  A clinical risk score to identify patients with COVID-19 at high risk of critical care admission or death: An observational cohort study , 2020, Journal of Infection.

[193]  G. FitzGerald,et al.  COVID-19, microangiopathy, hemostatic activation, and complement. , 2020, The Journal of clinical investigation.

[194]  D. Kastner,et al.  The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation , 2017, Nature Immunology.

[195]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[196]  V. Thiel,et al.  To sense or not to sense viral RNA — essentials of coronavirus innate immune evasion , 2014, Current Opinion in Microbiology.

[197]  A. Bertoletti,et al.  Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection , 2016, Vaccine.

[198]  L. Bradley,et al.  Lessons in antiviral immunity , 2021, Science.

[199]  M. Massari,et al.  Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study , 2020, Annals of the Rheumatic Diseases.

[200]  E. Tramontano,et al.  Strategies of highly pathogenic RNA viruses to block dsRNA detection by RIG-I-like receptors: Hide, mask, hit , 2013, Antiviral Research.

[201]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[202]  Emily G McDonald,et al.  A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 , 2020, The New England journal of medicine.

[203]  A. Fischer,et al.  Loss-of-function mutations within the IL-2 inducible kinase ITK in patients with EBV-associated lymphoproliferative diseases , 2012, Leukemia.

[204]  Jianfeng Zhang,et al.  Clinical characteristics of 3062 COVID‐19 patients: A meta‐analysis , 2020, Journal of medical virology.

[205]  K. Shadan,et al.  Available online: , 2012 .

[206]  David K. Meyerholz,et al.  Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice , 2016, Cell Host & Microbe.

[207]  Lixia Chen,et al.  Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods , 2020, Acta Pharmaceutica Sinica B.

[208]  A. Iwasaki,et al.  Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19 , 2020, The Journal of Immunology.

[209]  Yong-tang Zheng,et al.  Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients , 2020, Cellular & Molecular Immunology.

[210]  R. A. Ezekowitz,et al.  Role of the mannose-binding lectin in innate immunity. , 2003, The Journal of infectious diseases.

[211]  David R. Holtgrave,et al.  Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State , 2020, The Journal of Emergency Medicine.

[212]  E. Holmes,et al.  The proximal origin of SARS-CoV-2 , 2020, Nature Medicine.

[213]  S. Paludan,et al.  Mutations in RNA Polymerase III genes and defective DNA sensing in adults with varicella-zoster virus CNS infection , 2018, Genes & Immunity.

[214]  Zhìhóng Hú,et al.  Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro , 2020, Cell Discovery.

[215]  Alicia M. Fry,et al.  Persons Evaluated for 2019 Novel Coronavirus — United States, January 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[216]  Xu Liu,et al.  In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[217]  Arndt Borkhardt,et al.  Combined immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional CD27 , 2013, Haematologica.

[218]  M. Dolhnikoff,et al.  Pathological evidence of pulmonary thrombotic phenomena in severe COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[219]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[220]  J. Sung,et al.  ABO blood group and susceptibility to severe acute respiratory syndrome. Authors' reply , 2005 .

[221]  Ali Danesh,et al.  Interferon-Mediated Immunopathological Events Are Associated with Atypical Innate and Adaptive Immune Responses in Patients with Severe Acute Respiratory Syndrome , 2007, Journal of Virology.